AEON Financials

Income Statement
MetricQ1 2026Q4 2025Q3 2025Q2 2025Q1 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
5.9M
+7.7%
5.5M
+121.1%
2.5M
-42.5%
4.3M
+839.0%
462.0K
R&D
2.0M
+26.4%
1.6M
+169.5%
597.0K
-43.9%
1.1M
+29.0%
825.0K
SG&A
3.9M
+0.3%
3.9M
+101.3%
1.9M
-40.7%
3.3M
+4.3%
3.1M
Operating Income
-5933000
-7.7%
-5511000
-121.1%
-2493000
+42.5%
-4338000
-839.0%
-462000
EBITDA
-5914000
-7.7%
-5491000
-121.9%
-2474000
+42.7%
-4318000
-874.7%
-443000
Net Income
-11793000
+68.2%
-37137000
-718.4%
-4538000
+31.7%
-6642000
-173.0%
9.1M
EPS (Basic)
$-0.29
+89.9%
$-2.86
-633.3%
$-0.39
+35.0%
$-0.60
-126.3%
$2.28
EPS (Diluted)
$-0.29
+89.9%
$-2.86
-633.3%
$-0.39
+35.0%
$-0.60
-126.3%
$2.28
Shares (Diluted)
40.6M
+213.0%
13.0M
+11.5%
11.6M
+4.9%
11.1M
+178.3%
4.0M
AEON Biopharma (AEON) โ€” Financials